Results from current clinical trials are rapidly evolving, with mixed results. In this EASL Studio the faculty discuss:

• why certain trials have failed whereas others have succeeded,
• what we have learned about the connection between overall survival and progression-free survival as endpoints, and
• how the systemic therapy of HCC has evolved.

Faculty

• Prof. Peter Galle (Moderator)
• Prof. Bruno Sangro (Faculty)
• Dr Anna Saborowski (Faculty)
• Prof. Arndt Vogel (Faculty)

Related episodes

• S2E15 – JHEP Live – The best animal model for HCC — lost in translation
• Special Edition: Highlights of the Liver Cancer Summit 2022
• Policy Dialogues Episode 3: Liver Cancer: The risk of ignorance

All EASL Studio Podcasts are available on EASL Campus.